Patients with advanced HCC may benefit from regorafenib if they are tolerant to sorafenib [19]; from cabozantinib irrespective of their tolerance to sorafenib [20]; or from ramucirumab if their AFP level is >400 ng/mL [21]. Here, AFP is linked to hepatocellular carcinoma.